Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?
Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?
- Prof John E Deanfield